PHAXIAM THERAPEUTICS S.A. PHAXIAM Therapeutics S.A. Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.935 EUR | +0.69% |
|
+0.51% | -36.20% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.915
EUR
Average target price
6.85
EUR
Spread / Average Target
+134.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.05% | 21.66B | |
| -18.35% | 20.77B | |
| -7.77% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
- News PHAXIAM Therapeutics S.A.
- European ADRs Move Lower in Tuesday Trading
